德国数字疗法退款计划的三年发展及其前进道路
Linea Schmidt1,2,3, Marc Pawlitzki4, Bernhard Y Renard1,2,3
1Hasso Plattner Institute, Digital Engineering Faculty, University of Potsdam, Potsdam, Germany.
NPJ digital medicine
|May 24, 2024
概括
德国数字健康应用程序 (DiGA) 计划开创了数字治疗 (DTx) 整合和报销的先驱. 尽管面临挑战,但它的演变为数字健康采用提供了全球洞察力.
科学领域:
- 数字健康数字健康
- 医疗保健政策 医疗保健政策
- 医疗器械规则 医疗器械规则
背景情况:
- 2019年德国数字医疗保健法制定了"数字健康应用" (DiGA) 计划.
- 该计划为将数字疗法 (DTx) 整合到医疗保健系统中创造了一个新的框架.
- 它为数字健康应用程序提供可扩展和有效的报销策略.
研究的目的:
- 综合DiGA计划在前三年的演变.
- 分析DiGA处方和定价的趋势.
- 识别批评,缺陷和未来的立法修正案.
主要方法:
- 审查和综合DiGA计划的发展和影响.
- 分析处方数据和定价趋势.
- 讨论立法变化和整合挑战.
主要成果:
- 超过374,000个DiGA处方显示出显著的上升趋势.
- 迪加计划越来越多地融入德国医疗保健系统.
- 未来的修正案可能包括更高风险的医疗设备,可能会改变该计划.
结论:
- 迪加计划是DTx集成和退款的开创性模式.
- 与证据,有效性和系统集成相关的挑战仍然存在,但正在解决.
- 该计划为寻求采用数字治疗的全球医疗保健系统提供了宝贵的见解.
相关概念视频
Issues And Trends In Healthcare Delivery System
5.6K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
5.6K
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Drug Administration and Therapy Phases: Overview
448
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
448
Health Information Technology and Healthcare Information System
827
Health Information Technology (HIT)
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
827
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Drug Control Governance: Regulatory Bodies and Their Impact
156
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
156


